Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

AUA annual meeting featured a kidney cancer session and a presentation by Dr. Pratik Kanabur discussing a cost-effectiveness analysis of 89 Zr-girentuximab PET-CT (TLX250) to guide management of small ...

Title: Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin (Emi-Le), a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate Rapid Oral Session Title: Developmental Therapeutics Date and ...

A vet has issued a warning to all cat owners to be vigilant for three symptoms that could indicate their pet is suffering from kidney disease, a condition that can be fatal if not addressed.

Non-enhanced CT scans were deemed helpful in only 4% of haemorrhage cases, primarily in gastrointestinal bleeding, while contributing substantially to the overall radiation exposure. An analysis ...

Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai ...

We can do it for three times also, but one machine also needs some rest. I think that will go a long way, and later on we'll expand it even further, Beri added. Launched in May 2024, the Adharshila ...

Methods This single-centre, double-blind, phase II, randomised ... informed consent (figure 2). Three were subsequently excluded due to ECG findings or potassium level, and 148 participants with ...

36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. "The positive results from our Phase 2b study evaluating a melanocortin agonist in patients with diabetic ...

36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. "The positive results from our Phase 2b study evaluating a melanocortin agonist in patients with ...

36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. Palatin Technologies, Inc. "The positive results from our Phase 2b study evaluating a melanocortin ...